Detection of FLT3-ITD MRD Is Associated With Relapse and Death in AML
FLT3-ITD minimal residual disease is associated with an increased risk of relapse and death in patients with acute myeloid leukemia.
Diagnosis & Disease Information
Though Improved, Outcomes Remain Poor for Patients With MDS Who Progress on HMA Therapy
Researchers sought to determine outcomes in patients with MDS whose disease progressed during treatment with hypomethylating agents.
Midostaurin Maintenance Improved Survival in FLT3-Mutated Acute Myeloid Leukemia
Researchers sought to determine the efficacy of midostaurin maintenance therapy in patients with FLT3-mutated acute myeloid leukemia.
Integrating KMT2A-PTD into DNA NGS to Predict Outcomes in AML, MDS
Integrating the assessment of KMT2A-PTD into standard DNA sequencing may be prognostically valuable for patients with MDS or AML.
Adding Idasanutlin to Cytarabine Does Not Improve OS in Relapsed/Refractory AML
Researchers sought to determine whether adding idasanutlin to cytarabine would improve OS in patients with relapsed or refractory acute myeloid leukemia.
Similar OS, More Infections With CPX-351 vs Venetoclax Plus Azacitidine
Researchers found similar survival, but more infections and longer hospitalizations, with CPX-351 vs venetoclax plus azacitidine.
Enasidenib in Relapsed/Refractory IDH2-Mutated Acute Myeloid Leukemia
Enasidenib did not improve overall survival, but it was associated with improvements in event-free survival and time to treatment failure.
Extended Decitabine Appears Safer Than Standard Induction for Older AML Patients
Extended decitabine produced a similar overall survival rate as standard chemotherapy, but decitabine had a better safety profile.
Quizartinib Improves Overall Survival in FLT3-ITD+ Acute Myeloid Leukemia
Results from the phase 3 QuANTUM-First trial have the potential to change standard care for adults with newly diagnosed FLT3-ITD+ acute myeloid leukemia, according to the lead study author.
AML Treatment Associated With Body Composition Changes in Children
Changes in weight, BMI, and decreased height persist long-term after treatment for AML in pediatric patients.
- Loading...
Loading...
Next post in Hematologic Cancers
Loading... 
Loading...